Osteosarcoma: current insights and advances

Guraustin S. Brar , Aidan A. Schmidt , Logan R. Willams , Mark R. Wakefield , Yujiang Fang

Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) : 1002324

PDF (1817KB)
Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) :1002324 DOI: 10.37349/etat.2025.1002324
Review
research-article
Osteosarcoma: current insights and advances
Author information +
History +
PDF (1817KB)

Abstract

Osteosarcoma is the most prevalent primary malignant bone tumor affecting adolescents and young adults. Despite advancements in cancer therapies, its prognosis remains poor due to its aggressive nature and early propensity for metastasis-often present at the time of diagnosis. The etiology of osteosarcoma is multifactorial, involving genetic predispositions, environmental exposures, and familial syndromes. While treatment strategies are largely dictated by tumor stage, neoadjuvant chemotherapy followed by surgical resection remains the cornerstone of management. This review provides a comprehensive overview of osteosarcoma, including its historical context, subclassifications, clinical presentation, diagnostic approaches, and evolving treatment modalities. Recent therapeutic innovations-such as gene therapy, immunotherapy, radiation advances, and tyrosine kinase inhibitors-are discussed in detail, highlighting their mechanisms and clinical potential. By synthesizing current literature and identifying ongoing challenges, this review aims to inform clinicians and researchers of recent progress while highlighting critical gaps to guide future research and improve patient outcomes in osteosarcoma care.

Keywords

Osteosarcoma / gene therapy / immunotherapy / radiation / tyrosine kinase inhibitors

Cite this article

Download citation ▾
Guraustin S. Brar, Aidan A. Schmidt, Logan R. Willams, Mark R. Wakefield, Yujiang Fang. Osteosarcoma: current insights and advances. Exploration of Targeted Anti-tumor Therapy, 2025, 6 (1) : 1002324 DOI:10.37349/etat.2025.1002324

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Sadykova LR, Ntekim AI, Muyangwa-Semenova M, Rutland CS, Jeyapalan JN, Blatt N, et al. Epidemiology and Risk Factors of Osteosarcoma. Cancer Invest. 2020; 38: 259-69.

[2]

Chen G, Li M, Xiao X, Ji C, Huang M, Wang Z, et al. A classification system of joint-salvage tumor resection in osteosarcoma of the knee: A retrospective cohort study. Knee. 2023; 41: 221-31.

[3]

Cortini M, Avnet S, Baldini N. Mesenchymal stroma: role in osteosarcoma progression. Cancer Lett. 2017; 405: 90-9.

[4]

Abarrategi A, Tornin J, Martinez-Cruzado L, Hamilton A, Martinez-Campos E, Rodrigo JP, et al. Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies. Stem Cells Int. 2016; 2016: 3631764.

[5]

Deepak KV, Bharanidharan R. A survey on deep learning and machine learning techniques over histopathology image based Osteosarcoma Detection. Multimed Tools Appl. 2025; 84: 15763-86.

[6]

Jeffree GM, Price CH, Sissons HA. The metastatic patterns of osteosarcoma. Br J Cancer. 1975; 32: 87-107.

[7]

Mohseny AB, Szuhai K, Romeo S, Buddingh EP, Briaire-de Bruijn I, de Jong D, et al. Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. J Pathol. 2009; 219: 294-305.

[8]

Marko TA, Diessner BJ, Spector LG. Prevalence of Metastasis at Diagnosis of Osteosarcoma: An International Comparison. Pediatr Blood Cancer. 2016; 63: 1006-11.

[9]

Harper K, Sathiadoss P, Saifuddin A, Sheikh A. A review of imaging of surface sarcomas of bone. Skeletal Radiol. 2021; 50: 9-28.

[10]

Lindsey BA, Markel JE, Kleinerman ES. Osteosarcoma Overview. Rheumatol Ther. 2017; 4: 25-43.

[11]

Buchanan A, Abdelsayed R, Kalathingal S, Kurago Z. Radiographic features of intercrestal and classic osteosarcoma: a report of 3 cases. Or Surg Or Med Or Pa Or Radiol. 2021; 132: e108.

[12]

Cleton-Jansen AM, Buerger H, Hogendoorn PCW. Central high-grade osteosarcoma of bone: diagnostic and genetic considerations. Curr Diagn Pathol. 2005; 11: 390-9.

[13]

Kumar VS, Barwar N, Khan SA. Surface osteosarcomas: Diagnosis, treatment and outcome. Indian J Orthop. 2014; 48: 255-61.

[14]

Hang JF, Chen PC. Parosteal Osteosarcoma. Arch Pathol Lab Med. 2014; 138: 694-9.

[15]

Cesari M, Alberghini M, Vanel D, Palmerini E, Staals EL, Longhi A, et al. Periosteal osteosarcoma: A single-institution experience. Cancer. 2011; 117: 1731-5.

[16]

Deng Z, Huang Z, Ding Y, Su Y, Chan CM, Niu X. High-Grade Surface Osteosarcoma: Clinical Features and Oncologic Outcome. J Bone Oncol. 2020; 23: 100288.

[17]

Beird HC, Bielack SS, Flanagan AM, Gill J, Heymann D, Janeway KA, et al. Osteosarcoma. Nat Rev Dis Primers. 2022; 8: 77.

[18]

Crombé A, Simonetti M, Longhi A, Hauger O, Fadli D, Spinnato P. Imaging of Osteosarcoma: Presenting Findings, Metastatic Patterns, and Features Related to Prognosis. J Clin Med. 2024; 13: 5710.

[19]

Barger A, Baker K, Driskell E, Sander W, Roady P, Berry M, et al. The use of alkaline phosphatase and runx2 to distinguish osteosarcoma from other common malignant primary bone tumors in dogs. Vet Pathol. 2022; 59: 427-32.

[20]

Lin T, Jin Q, Mo X, Zhao Z, Xie X, Zou C, et al. Experience with periprosthetic infection after limb salvage surgery for patients with osteosarcoma. J Orthop Surg Res. 2021; 16: 93.

[21]

Marchandet L, Lallier M, Charrier C, Baud’huin M, Ory B, Lamoureux F. Mechanisms of Resistance to Conventional Therapies for Osteosarcoma. Cancers (Basel). 2021; 13: 683.

[22]

Benjamin RS. Adjuvant and Neoadjuvant Chemotherapy for Osteosarcoma: A Historical Perspective. Adv Exp Med Biol. 2020; 1257: 1-10.

[23]

Papakonstantinou E, Stamatopoulos A, I Athanasiadis D, Kenanidis E, Potoupnis M, Haidich A, et al. Limb-salvage surgery offers better five-year survival rate than amputation in patients with limb osteosarcoma treated with neoadjuvant chemotherapy. A systematic review and meta-analysis. J Bone Oncol. 2020; 25: 100319.

[24]

Jafari F, Javdansirat S, Sanaie S, Naseri A, Shamekh A, Rostamzadeh D, et al. Osteosarcoma: A comprehensive review of management and treatment strategies. Ann Diagn Pathol. 2020; 49: 151654.

[25]

Yan JP, Xiang RM. Effect assessment of methotrexate in combination with other chemotherapeutic agents for osteosarcoma in children: A protocol for systematic review and meta-analysis. Medicine (Baltimore). 2021; 100: e25534.

[26]

Rothzerg E, Pfaff AL, Koks S. Innovative approaches for treatment of osteosarcoma. Exp Biol Med (Maywood). 2022; 247: 310-6.

[27]

Celik B, Cicek K, Leal AF, Tomatsu S. Regulation of Molecular Targets in Osteosarcoma Treatment. Int J Mol Sci. 2022; 23: 12583.

[28]

Yu S, Yao X. Advances on immunotherapy for osteosarcoma. Mol Cancer. 2024; 23: 192.

[29]

Fu H, Wu Y, Chen J, Hu X, Wang X, Xu G. Exosomes and osteosarcoma drug resistance. Front Oncol. 2023; 13: 1133726.

[30]

Théry C, Amigorena S, Raposo G, Clayton A. Isolation and Characterization of Exosomes from Cell Culture Supernatants and Biological Fluids. Curr Protoc Cell Biol. 2006; 30: 3.22.1-29.

[31]

Zhang B, Yang Y, Tao R, Yao C, Zhou Z, Zhang Y. Exosomes loaded with miR-665 inhibit the progression of osteosarcoma in vivo and in vitro. Am J Transl Res. 2022; 14: 7012-26.

[32]

Saber Sichani A, Ranjbar M, Baneshi M, Torabi Zadeh F, Fallahi J. A Review on Advanced CRISPR-Based Genome-Editing Tools: Base Editing and Prime Editing. Mol Biotechnol. 2023; 65: 849-60.

[33]

Liu W, Wang S, Lin B, Zhang W, Ji G. Applications of CRISPR/Cas9 in the research of malignant musculoskeletal tumors. BMC Musculoskelet Disord. 2021; 22: 149.

[34]

Chehelgerdi M, Chehelgerdi M, Khorramian-Ghahfarokhi M, Shafieizadeh M, Mahmoudi E, Eskandari F, et al. Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy. Mol Cancer. 2024; 23: 9.

[35]

Wang R, Wang D, Bai X, Guo J, Xia S, Cheng Y, et al. Kinome-wide CRISPR-Cas9 knockout screens revealed PLK1 as a therapeutic target for osteosarcoma. Cell Death Discov. 2023; 9: 231.

[36]

Wang J, Guo W, Wang X, Tang X, Sun X, Ren T. Circulating Exosomal PD-L1 at Initial Diagnosis Predicts Outcome and Survival of Patients with Osteosarcoma. Clin Cancer Res. 2023; 29: 659-66.

[37]

Yu X, Zhai X, Wu J, Feng Q, Hu C, Zhu L, et al. Evolving perspectives regarding the role of the PD-1/PD-L1 pathway in gastric cancer immunotherapy. Biochim Biophys Acta Mol Basis Dis. 2024; 1870: 166881.

[38]

Boye K, Longhi A, Guren T, Lorenz S, Næss S, Pierini M, et al. Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial. Cancer Immunol Immunother. 2021; 70: 2617-24.

[39]

Park JA, Cheung NV. Promise and Challenges of T Cell Immunotherapy for Osteosarcoma. Int J Mol Sci. 2023; 24: 12520.

[40]

Curigliano G, Gelderblom H, Mach N, Doi T, Tai D, Forde PM, et al. Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors. Clin Cancer Res. 2021; 27: 3620-9.

[41]

Khan SH, Choi Y, Veena M, Lee JK, Shin DS. Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors. Front Immunol. 2025; 15: 1489827.

[42]

Kaczanowska S, Murty T, Alimadadi A, Contreras CF, Duault C, Subrahmanyam PB, et al. Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy. Cancer Cell. 2024; 42: 35-51.e8.

[43]

Chan H, Trout CV, Mikolon D, Adams P, Guzman R, Mavrommatis K, et al. Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies. Cancer Res Commun. 2024; 4: 505-15.

[44]

Eng C, Lakhani NJ, Philip PA, Schneider C, Johnson B, Kardosh A, et al. A Phase 1b/2 Study of the Anti-CD47 Antibody Magrolimab with Cetuximab in Patients with Colorectal Cancer and Other Solid Tumors. Target Oncol. 2025; 20: 519-30.

[45]

Musser ML, Berger EP, Tripp CD, Clifford CA, Bergman PJ, Johannes CM. Safety evaluation of the canine osteosarcoma vaccine, live Listeria vector. Vet Comp Oncol. 2021; 19: 92-8.

[46]

Choi J, Lee SY. Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors. Immune Netw. 2020; 20: e9.

[47]

Tian B, Du X, Zheng S, Zhang Y. The Role of Tumor Microenvironment in Regulating the Plasticity of Osteosarcoma Cells. Int J Mol Sci. 2022; 23: 16155.

[48]

Han Z, Chen G, Wang D. Emerging immunotherapies in osteosarcoma: from checkpoint blockade to cellular therapies. Front Immunol. 2025; 16: 1579822.

[49]

Liu H, Dong A, Rasteh AM, Wang P, Weng J. Identification of the novel exhausted T cell CD8+ markers in breast cancer. Sci Rep. 2024; 14: 19142.

[50]

Wu Y, Song Y, Wang R, Wang T. Molecular mechanisms of tumor resistance to radiotherapy. Mol Cancer. 2023; 22: 96.

[51]

Dong M, Liu R, Zhang Q, Luo H, Wang D, Wang Y, et al. Efficacy and safety of carbon ion radiotherapy for bone sarcomas: a systematic review and meta-analysis. Radiat Oncol. 2022; 17: 172.

[52]

Seidensaal K, Mattke M, Haufe S, Rathke H, Haberkorn U, Bougatf N, et al. The role of combined ion-beam radiotherapy (CIBRT) with protons and carbon ions in a multimodal treatment strategy of inoperable osteosarcoma. Radiother Oncol. 2021; 159: 8-16.

[53]

Astl J, Belsan T, Michnova L, Kubeš J, Filipovsky T, Blecha J, et al. Highly Aggressive Osteosarcoma of the Ethmoids and Maxillary Sinus-A Case of Successful Surgery and Proton Beam Radiotherapy in a 65-Year-Old Man. Medicina (Kaunas). 2022; 58: 1141.

[54]

Tian X, Liu K, Hou Y, Cheng J, Zhang J. The evolution of proton beam therapy: Current and future status. Mol Clin Oncol. 2018; 8: 15-21.

[55]

Mehta R, Ponnuvelu S, Kuotsu R, Nagarkar NM. Osteosarcoma of the sphenoid sinus extending to ethmoid sinus-report of a rare case with review of literature giving special emphasis on treatment and outcome. Egypt J Otolaryngol. 2023; 39: 172.

[56]

Hoppe BS, Petersen IA, Wilke BK, DeWees TA, Imai R, Hug EB, et al. Pragmatic, Prospective Comparative Effectiveness Trial of Carbon Ion Therapy, Surgery, and Proton Therapy for the Management of Pelvic Sarcomas (Soft Tissue/Bone) Involving the Bone: The PROSPER Study Rationale and Design. Cancers (Basel). 2023; 15: 1660.

[57]

Malouff TD, Mahajan A, Krishnan S, Beltran C, Seneviratne DS, Trifiletti DM. Carbon Ion Therapy: A Modern Review of an Emerging Technology. Front Oncol. 2020; 10: 82.

[58]

Kowalchuk RO, Corbin KS, Jimenez RB. Particle Therapy for Breast Cancer. Cancers (Basel). 2022; 14: 1066.

[59]

Zhao X, Wu Q, Gong X, Liu J, Ma Y. Osteosarcoma: a review of current and future therapeutic approaches. Biomed Eng Online. 2021; 20: 24.

[60]

Zhang XY, Sun K, Zhu Q, Song T, Liu Y. Ginseng polysaccharide serves as a potential radiosensitizer through inducing apoptosis and autophagy in the treatment of osteosarcoma. Kaohsiung J Med Sci. 2017; 33: 535-42.

[61]

Peeters A, Grutters JPC, Pijls-Johannesma M, Reimoser S, De Ruysscher D, Severens JL, et al. How costly is particle therapy? Cost analysis of external beam radiotherapy with carbon-ions, protons and photons. Radiother Oncol. 2010; 95: 45-53.

[62]

Gaito S, Aznar MC, Burnet NG, Crellin A, France A, Indelicato D, et al. Assessing Equity of Access to Proton Beam Therapy: A Literature Review. Clin Oncol (R Coll Radiol). 2023; 35: e528-36.

[63]

Beltran C, Amos RA, Rong Y. We are ready for clinical implementation of Carbon Ion Radiotherapy in the United States. J Appl Clin Med Phys. 2020; 21: 6-9.

[64]

Bharathi RP, Ms A, Kamath A. A Systematic Review of the Economic Burden of Proton Therapy in Head and Neck Cancer. Asian Pac J Cancer Prev. 2023; 24: 3643-53.

[65]

Okazaki S, Shibuya K, Takura T, Miyasaka Y, Kawamura H, Ohno T. Cost-effectiveness of carbon-ion radiotherapy versus stereotactic body radiotherapy for non-small-cell lung cancer. Cancer Sci. 2022; 113: 674-83.

[66]

Komorowska D, Radzik T, Kalenik S, Rodacka A. Natural Radiosensitizers in Radiotherapy: Cancer Treatment by Combining Ionizing Radiation with Resveratrol. Int J Mol Sci. 2022; 23: 10627.

[67]

Giordano F, Lenna S, Baudo G, Rampado R, Massaro M, De Rosa E, et al. Tyrosine kinase inhibitor-loaded biomimetic nanoparticles as a treatment for osteosarcoma. Cancer Nano. 2022; 13: 40.

[68]

Sheng G, Gao Y, Yang Y, Wu H. Osteosarcoma and Metastasis. Front Oncol. 2021; 11: 780264.

[69]

Jiao Q, Bi L, Ren Y, Song S, Wang Q, Wang YS. Advances in studies of tyrosine kinase inhibitors and their acquired resistance. Mol Cancer. 2018; 17: 36.

[70]

Kyriazoglou A, Gkaralea LE, Kotsantis I, Anastasiou M, Pantazopoulos A, Prevezanou M, et al. Tyrosine kinase inhibitors in sarcoma treatment. Oncol Lett. 2022; 23: 183.

[71]

Tian Z, Niu X, Yao W. Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target? Front Oncol. 2020; 10: 1642.

[72]

Wang G, Sun M, Jiang Y, Zhang T, Sun W, Wang H, et al. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma. Int J Cancer. 2019; 145: 979-93.

[73]

Yang J, Yang D, Sun Y, Sun B, Wang G, Trent JC, et al. Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma. Cancer. 2011; 117: 4925-38.

[74]

Yu XW, Wu TY, Yi X, Ren WP, Zhou ZB, Sun YQ, et al. Prognostic significance of VEGF expression in osteosarcoma: a meta-analysis. Tumour Biol. 2014; 35: 155-60.

[75]

Suehara Y, Alex D, Bowman A, Middha S, Zehir A, Chakravarty D, et al. Clinical Genomic Sequencing of Pediatric and Adult Osteosarcoma Reveals Distinct Molecular Subsets with Potentially Targetable Alterations. Clin Cancer Res. 2019; 25: 6346-56.

[76]

Assi T, Watson S, Samra B, Rassy E, Le Cesne A, Italiano A, et al. Targeting the VEGF Pathway in Osteosarcoma. Cells. 2021; 10: 1240.

[77]

Assi A, Farhat M, Hachem MCR, Zalaquett Z, Aoun M, Daher M, et al. Tyrosine kinase inhibitors in osteosarcoma: Adapting treatment strategiesa. J Bone Oncol. 2023; 43: 100511.

[78]

Imamura T. Physiological Functions and Underlying Mechanisms of Fibroblast Growth Factor (FGF) Family Members: Recent Findings and Implications for Their Pharmacological Application. Biol Pharm Bull. 2014; 37: 1081-9.

[79]

Yu X, Yustein JT, Xu J. Research models and mesenchymal/epithelial plasticity of osteosarcoma. Cell Biosci. 2021; 11: 94.

[80]

Chen X, Liu L, Liu P, Chen Y, Lin D, Yan H, et al. Discovery of Potent and Orally Bioavailable Platelet-Derived Growth Factor Receptor (PDGFR) Inhibitors for the Treatment of Osteosarcoma. J Med Chem. 2022; 65: 5374-91.

[81]

Zvi Y, Ugur E, Batko B, Gill J, Roth M, Gorlick R, et al. Prognostic and Therapeutic Utility of Variably Expressed Cell Surface Receptors in Osteosarcoma. Sarcoma. 2021; 2021: 8324348.

[82]

Wang JH, Zeng Z, Sun J, Chen Y, Gao X. A novel small-molecule antagonist enhances the sensitivity of osteosarcoma to cabozantinib in vitro and in vivo by targeting DNMT-1 correlated with disease severity in human patients. Pharmacol Res. 2021; 173: 105869.

[83]

Luo J, Xia Y, Yin Y, Luo J, Liu M, Zhang H, et al. ATF4 destabilizes RET through nonclassical GRP78 inhibition to enhance chemosensitivity to bortezomib in human osteosarcoma. Theranostics. 2019; 9: 6334-53.

[84]

Ji Z, Shen J, Lan Y, Yi Q, Liu H. Targeting signaling pathways in osteosarcoma: Mechanisms and clinical studies. MedComm (2020). 2023; 4: e308.

[85]

Wang YH, Han XD, Qiu Y, Xiong J, Yu Y, Wang B, et al. Increased expression of insulin-like growth factor-1 receptor is correlated with tumor metastasis and prognosis in patients with osteosarcoma. J Surg Oncol. 2012; 105: 235-43.

[86]

Li Q, Wang X, Jiang N, Xie X, Liu N, Liu J, et al. Exosome-transmitted linc00852 associated with receptor tyrosine kinase AXL dysregulates the proliferation and invasion of osteosarcoma. Cancer Med. 2020; 9: 6354-66.

[87]

Moukengue B, Lallier M, Marchandet L, Baud’huin M, Verrecchia F, Ory B, et al. Origin and Therapies of Osteosarcoma. Cancers (Basel). 2022; 14: 3503.

[88]

Lamhamedi-Cherradi SE, Mohiuddin S, Mishra DK, Krishnan S, Velasco AR, Vetter AM, et al. Transcriptional activators YAP/TAZ and AXL orchestrate dedifferentiation, cell fate, and metastasis in human osteosarcoma. Cancer Gene Ther. 2021; 28: 1325-38.

[89]

Just MA, Van Mater D, Wagner LM. Receptor tyrosine kinase inhibitors for the treatment of osteosarcoma and Ewing sarcoma. Pediatr Blood Cancer. 2021; 68: e29084.

[90]

Nirala BK, Yamamichi T, Yustein JT. Deciphering the Signaling Mechanisms of Osteosarcoma Tumorigenesis. Int J Mol Sci. 2023; 24: 11367.

[91]

Shyam Sunder S, Sharma UC, Pokharel S. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. Signal Transduct Target Ther. 2023; 8: 262.

PDF (1817KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉